{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:52:12Z","timestamp":1780527132798,"version":"3.54.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jaac.2020.08.441","type":"journal-article","created":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T20:04:23Z","timestamp":1600632263000},"page":"76-104.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Systematic Review: System-wide Interventions to Monitor Pediatric Antipsychotic Prescribing and Promote Best Practice"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6010-6304","authenticated-orcid":false,"given":"Thomas I.","family":"Mackie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana J.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Karpman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3416-2799","authenticated-orcid":false,"given":"Christopher","family":"Bellonci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2020.08.441_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1753-2000-2-26","article-title":"A\u00a0three-country comparison of psychotropic medication prevalence in youth","volume":"2","author":"Zito","year":"2008","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"10.1016\/j.jaac.2020.08.441_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/cap.2009.0003","article-title":"Psychotropic drug use among Icelandic children: A nationwide population-based study","volume":"19","author":"Zoega","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2020.08.441_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/1472-6963-13-509","article-title":"Health examination utilization in the visually disabled population in Taiwan: A nationwide population-based study","volume":"13","author":"Hsu","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jaac.2020.08.441_bib4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","article-title":"Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom","volume":"121","author":"Rani","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2020.08.441_bib5","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/j.1475-6773.2012.01461.x","article-title":"The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: A national study of U.S. Medicaid-enrolled children","volume":"47","author":"Matone","year":"2012","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jaac.2020.08.441_bib6","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2020.08.441_bib7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1089\/cap.2018.0037","article-title":"A\u00a0focused review on the treatment of pediatric patients with atypical antipsychotics","volume":"28","author":"Lee","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2020.08.441_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995-2008","volume":"20","author":"Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaac.2020.08.441_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pedhc.2011.10.009","article-title":"Antipsychotic medication prescribing trends in children and adolescents","volume":"26","author":"Harrison","year":"2012","journal-title":"J\u00a0Pediatr Health Care"},{"key":"10.1016\/j.jaac.2020.08.441_bib10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2020.08.441_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/ps.2010.61.2.123","article-title":"Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005","volume":"61","author":"Pathak","year":"2010","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1542\/peds.2014-2260","article-title":"Antipsychotic medication prescribing in children enrolled in Medicaid","volume":"135","author":"Rettew","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2020.08.441_bib13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1176\/appi.ps.002762012","article-title":"A+KIDS, a web-based antipsychotic registry for North Carolina youths: An alternative to prior authorization","volume":"64","author":"Christian","year":"2013","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fpsyt.2012.00062","article-title":"Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs","volume":"3","author":"Gohlke","year":"2012","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jaac.2020.08.441_bib15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1377\/hlthaff.2016.0064","article-title":"Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain","volume":"35","author":"Crystal","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jaac.2020.08.441_bib16","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2105\/AJPH.91.7.1094","article-title":"Mental health services for youths in foster care and disabled youths","volume":"91","author":"dosReis","year":"2001","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jaac.2020.08.441_bib17","first-page":"13","article-title":"Trends in antipsychotic drug use by very young, privately insured children","volume":"49","author":"Olfson","year":"2010","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.08.441_bib18","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1542\/peds.2007-0212","article-title":"Psychotropic medication patterns among youth in foster care","volume":"121","author":"Zito","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2020.08.441_bib19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1176\/appi.ps.201400028","article-title":"Medicaid expenditures on psychotropic medications for maltreated children: A study of 36 states","volume":"65","author":"Raghavan","year":"2014","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib20","series-title":"Foster children: HHS guidance could help states improve oversight of psychotropic prescriptions","year":"2011"},{"key":"10.1016\/j.jaac.2020.08.441_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10488-016-0721-x","article-title":"Fostering psychotropic medication oversight for children in foster care: A national examination of states\u2019 monitoring mechanisms","volume":"44","author":"Mackie","year":"2017","journal-title":"Adm Policy Ment Health"},{"key":"10.1016\/j.jaac.2020.08.441_bib22","unstructured":"Fostering Connections to Success and Increasing Adoptions Act of 2008. Pub L No. 110-351, 42 USC \u00a713052008."},{"key":"10.1016\/j.jaac.2020.08.441_bib23","series-title":"Foster children: Additional federal guidance could help states better plan for oversight of psychotropic medications administered by managed-care organizations","year":"2014"},{"key":"10.1016\/j.jaac.2020.08.441_bib24","series-title":"Children\u2019s mental health: Concerns remain about appropriate services for children in medicaid and foster care","year":"2012"},{"key":"10.1016\/j.jaac.2020.08.441_bib27","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ps.201500270","article-title":"A\u00a0national survey of state Medicaid psychotropic-monitoring programs targeting youths","volume":"67","author":"dosReis","year":"2016","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib28","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jama.2015.0763","article-title":"Medicaid prior authorization policies for pediatric use of antipsychotic medications","volume":"313","author":"Schmid","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2020.08.441_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10488-016-0721-x","article-title":"Fostering psychotropic medication oversight for children in foster care: A national examination of states\u2019 monitoring mechanisms","volume":"44","author":"Mackie","year":"2017","journal-title":"Adm Policy Ment Health"},{"key":"10.1016\/j.jaac.2020.08.441_bib30","first-page":"175","article-title":"Psychotropic medication management for youth in state care: Consent, oversight, and policy considerations","volume":"86","author":"Naylor","year":"2007","journal-title":"Child Welfare"},{"key":"10.1016\/j.jaac.2020.08.441_bib31","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.childyouth.2011.07.003","article-title":"Psychotropic medication oversight for youth in foster care: A national perspective on state child welfare policy and practice guidelines","volume":"33","author":"Mackie","year":"2011","journal-title":"Children and Youth Services Review"},{"key":"10.1016\/j.jaac.2020.08.441_bib32","article-title":"The Fostering Connections to Success and Increasing Adoptions Act: Implementation issues and a look ahead at additional child welfare reform. Working paper","author":"Geen","year":"2009","journal-title":"Child Trends"},{"key":"10.1016\/j.jaac.2020.08.441_bib33","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamapsychiatry.2018.1867","article-title":"Effect of peer comparison letters for high-volume primary care prescribers of quetiapine in older and disabled adults: A randomized clinical trial","volume":"75","author":"Sacarny","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"8 Suppl 2","key":"10.1016\/j.jaac.2020.08.441_bib34","first-page":"II2","article-title":"Changing provider behavior: An overview of systematic reviews of interventions","volume":"39","author":"Grimshaw","year":"2001","journal-title":"Med Care"},{"key":"10.1016\/j.jaac.2020.08.441_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1472-6963-8-75","article-title":"Interventions designed to improve the quality and efficiency of medication use in managed care: A critical review of the literature\u20142001\u20132007","volume":"8","author":"Lu","year":"2008","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jaac.2020.08.441_bib36","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1056\/NEJMsa1413512","article-title":"Trends in mental health care among children and adolescents","volume":"372","author":"Olfson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaac.2020.08.441_bib37","unstructured":"Farace D. Forward. Paper presented at: Perspectives on the Design and Transfer of Scientific and Technical Information; 1998; Amsterdam."},{"issue":"2","key":"10.1016\/j.jaac.2020.08.441_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.MR000006.pub2","article-title":"Time to publication for results of clinical trials","author":"Hopewell","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaac.2020.08.441_bib39","article-title":"Grey literature in meta-analyses of randomized trials of health care interventions","volume":"2","author":"Hopewell","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaac.2020.08.441_bib40","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1176\/appi.ps.201700357","article-title":"Psychotropic polypharmacy among youth with serious emotional and behavioral disorders receiving coordinated care services","volume":"69","author":"Wu","year":"2018","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib41","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.ijnurstu.2011.06.004","article-title":"A\u00a0general critical appraisal tool: An evaluation of construct validity","volume":"48","author":"Crowe","year":"2011","journal-title":"Int J Nurs Stud"},{"key":"10.1016\/j.jaac.2020.08.441_bib42","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1744-1609.2011.00237.x","article-title":"Comparison of the effects of using the Crowe Critical Appraisal Tool versus informal appraisal in assessing health research: A randomised trial","volume":"9","author":"Crowe","year":"2011","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.jaac.2020.08.441_bib43","author":"Crowe"},{"key":"10.1016\/j.jaac.2020.08.441_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jclinepi.2017.02.015","article-title":"Quasi-experimental study designs series\u2014paper 6: Risk of bias assessment","volume":"89","author":"Waddington","year":"2017","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaac.2020.08.441_bib45","series-title":"Experimental and Quasi-Experimental Designs for Generalized Causal Inference","author":"Shadish","year":"2002"},{"key":"10.1016\/j.jaac.2020.08.441_bib46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamapsychiatry.2017.3493","article-title":"Pediatric use of antipsychotic medications before and after Medicaid peer review implementation","volume":"75","author":"Zito","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2020.08.441_bib47","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1176\/appi.ps.201100346","article-title":"Impact of the Florida Medicaid prior-authorization program on use of antipsychotics by children under age six","volume":"63","author":"Constantine","year":"2012","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1475-6773.12539","article-title":"Decrease in statewide antipsychotic prescribing after implementation of child and adolescent psychiatry consultation services","volume":"52","author":"Barclay","year":"2017","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jaac.2020.08.441_bib49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/cap.2014.0008","article-title":"The effects of prior authorization policies on Medicaid-enrolled children\u2019s use of antipsychotic medications: Evidence from two mid-Atlantic states","volume":"24","author":"Stein","year":"2014","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2020.08.441_bib50","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/appi.ps.201600489","article-title":"Second-generation antipsychotic prescribing patterns for pediatric patients enrolled in west virginia Medicaid","volume":"68","author":"Melvin","year":"2017","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1176\/appi.ps.201700177","article-title":"The impact of a state Medicaid peer-review authorization program on pediatric use of antipsychotic medications","volume":"69","author":"Pennap","year":"2018","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib52","unstructured":"Arkansas Medicaid Program. Arkansas Medicaid Summary of Antipsychotic Edits for All Children Less Than 18 Years of Age. Washington, DC: Centers for Medicare and Medicaid Services."},{"key":"10.1016\/j.jaac.2020.08.441_bib53","unstructured":"Mississippi Division of Medicaid. POS Changes and Other DUR Actions to Address Appropriate use of Antipsychotic Medications in Children. Washington, DC: Centers for Medicare and Medicaid Services."},{"key":"10.1016\/j.jaac.2020.08.441_bib54","series-title":"Update on Use of Psychotropic Medications for Children in Texas Foster Care","year":"2017"},{"key":"10.1016\/j.jaac.2020.08.441_bib55","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/cap.2017.0034","article-title":"Improving cardiometabolic monitoring of children on antipsychotics","volume":"27","author":"Cotes","year":"2017","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2020.08.441_bib56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10597-015-9833-0","article-title":"Antipsychotic cardiometabolic side effect monitoring in a state community mental health system","volume":"51","author":"Cotes","year":"2015","journal-title":"Community Ment Health J"},{"key":"10.1016\/j.jaac.2020.08.441_bib57","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/070674371205700504","article-title":"Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children","volume":"57","author":"Ronsley","year":"2012","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jaac.2020.08.441_bib58","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1176\/appi.ps.201700547","article-title":"A\u00a0Medicaid quality improvement collaborative on psychotropic medication prescribing for children","volume":"69","author":"Thackeray","year":"2018","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1176\/appi.ps.201400428","article-title":"The role of clinical setting and management approach in metabolic testing among youths and adults treated with antipsychotics","volume":"67","author":"Nicol","year":"2016","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10488-017-0807-0","article-title":"Impact of coordinated behavioral health management on quality measures of antipsychotic use","volume":"45","author":"Tai","year":"2018","journal-title":"Adm Policy Ment Health"},{"issue":"4","key":"10.1016\/j.jaac.2020.08.441_bib61","article-title":"Trends and intervention results for unusual antipsychotic polypharmacy prescribing patterns for Florida adult and child medicaid population: 2007-2013","volume":"42","author":"Lee","year":"2016","journal-title":"Journal of Health Care Finance"},{"key":"10.1016\/j.jaac.2020.08.441_bib62","unstructured":"Montana Department of Health and Human Services. Montana Medicaid\u2014Psychotropic Medication Utilization in Foster Care Children. Washington, D.C."},{"key":"10.1016\/j.jaac.2020.08.441_bib63","doi-asserted-by":"crossref","first-page":"e1577","DOI":"10.1542\/peds.2010-1361","article-title":"Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management","volume":"129","author":"Scotto Rosato","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2020.08.441_bib64","series-title":"AACAP Committee on Quality Issues. Practice Parameter for the Use of Atypical Antipsychotic Medications in Children and Adolescents","author":"Findling","year":"2011"},{"key":"10.1016\/j.jaac.2020.08.441_bib65","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1176\/appi.ps.201900417","article-title":"Policy and practice innovations to improve prescribing of psychoactive medications for children","volume":"71","author":"Kelleher","year":"2020","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib66","unstructured":"Pillay J, Boylan K, Carrey N, et\u00a0al. First and Second Generation Antipsychotics in Children and Young Adults: Systematic Review. Comparative Effectiveness Review No. 184. Update. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2015-00001-I.) AHRQ Publication No. 17-EHC001-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2017 [errata January 2018]."},{"key":"10.1016\/j.jaac.2020.08.441_bib67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaac.2019.04.022","article-title":"Antipsychotic use among youths in foster care enrolled in a specialized managed care organization intervention","volume":"59","author":"Mackie","year":"2020","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.08.441_bib68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaac.2019.09.034","article-title":"Beyond the prior authorization: Multimodal efforts to reduce antipsychotic medication prescribing in foster care youth","volume":"59","author":"Rettew","year":"2020","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.08.441_bib70","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1176\/appi.ps.201200032","article-title":"Public-academic partnerships: Evidence-based implementation: The role of sustained community-based practice and research partnerships","volume":"63","author":"Kilbourne","year":"2012","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.08.441_bib71","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1177\/1362361318766238","article-title":"Implementing systems-based innovations to improve access to early screening, diagnosis, and treatment services for children with autism spectrum disorder: An Autism Spectrum Disorder Pediatric, Early Detection, Engagement, and Services network study","volume":"23","author":"Broder Fingert","year":"2019","journal-title":"Autism"},{"key":"10.1016\/j.jaac.2020.08.441_bib72","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: Template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jaac.2020.08.441_bib75","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/2013.jamapediatrics.47","article-title":"The Partnership Access Line: Evaluating a child psychiatry consult program in Washington State","volume":"167","author":"Hilt","year":"2013","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.jaac.2020.08.441_bib76","first-page":"948","article-title":"Factors influencing the use of second-generation antipsychotics in children with psychosis","volume":"22","author":"Ramachandran","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jaac.2020.08.441_bib77","doi-asserted-by":"crossref","unstructured":"From Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;6:. https:\/\/doi.org\/10.1371\/journal.pmed1000097. For more information, visit www.prisma-statement.org.","DOI":"10.1371\/journal.pmed.1000097"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856720318803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856720318803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:31:27Z","timestamp":1760193087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856720318803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0890856720318803"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2020.08.441","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review: System-wide Interventions to Monitor Pediatric Antipsychotic Prescribing and Promote Best Practice","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2020.08.441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92020 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}